Harvard Bioscience, Inc.
$6.99
▲
2.16%
2026-04-21 07:15:00
www.harvardbioscience.com
NCM: HBIO
Explore Harvard Bioscience, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$30.92 M
Current Price
$6.99
52W High / Low
$9.46 / $2.81
Stock P/E
—
Book Value
$3.07
Dividend Yield
—
ROCE
0.17%
ROE
-1.47%
Face Value
—
EPS
$-12.8
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
316
Beta
1.5
Debt / Equity
322.39
Current Ratio
2.2
Quick Ratio
1.25
Forward P/E
5.39
Price / Sales
0.22
Enterprise Value
$54.94 M
EV / EBITDA
7.38
EV / Revenue
0.64
Rating
None
Target Price
$6
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Leverage is relatively high.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | BioLife Solutions, Inc. | $22.19 | — | $1.04 B | — | -4.34% | -3.37% | $29.62 / $17.86 | $7.72 |
| 2. | West Pharmaceutical Services, Inc. | $274.81 | 40.51 | $19.81 B | 0.33% | 17.6% | 16.86% | $322.34 / $193.05 | $44.11 |
| 3. | Avantor, Inc. | $8.5 | — | $5.76 B | — | 5.22% | -9.2% | $16.17 / $7.26 | $8.24 |
| 4. | Microbot Medical Inc. | $2.3 | — | $154.46 M | — | -18.87% | -32.42% | $4.67 / $1.6 | $1.16 |
| 5. | Kestra Medical Technologies, Ltd. | $23.31 | — | $1.33 B | — | -41.27% | -92.65% | $30 / $13.25 | $4.94 |
| 6. | Baxter International Inc. | $18.8 | — | $9.79 B | 0.21% | 1.04% | -13.71% | $32.68 / $15.73 | $11.92 |
| 7. | STAAR Surgical Company | $25.53 | — | $1.27 B | — | -11.99% | -21.7% | $30.81 / $15.59 | $6.97 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 23.73 M | 20.59 M | 20.45 M | 21.77 M | 24.56 M | — |
| Operating Profit | 1.93 M | 0.24 M | -0.62 M | -1.45 M | -1.38 M | — |
| Net Profit | -2.85 M | -1.23 M | -2.28 M | -50.34 M | 0.02 M | — |
| EPS in Rs | -0.64 | -0.28 | -0.51 | -11.26 | 0 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 86.55 M | 94.14 M | 112.25 M | 113.33 M |
| Operating Profit | 0.1 M | -6.21 M | 1.89 M | -7.17 M |
| Net Profit | -56.7 M | -12.4 M | -3.42 M | -9.52 M |
| EPS in Rs | -12.68 | -2.77 | -0.76 | -2.13 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 80.07 M | 126.64 M | 137.37 M | 145.36 M |
| Total Liabilities | 66.34 M | 63.3 M | 64.29 M | 73.14 M |
| Equity | 13.73 M | 63.34 M | 73.07 M | 72.22 M |
| Current Assets | 48.23 M | 45.12 M | 49.04 M | 51.12 M |
| Current Liabilities | 21.96 M | 54.96 M | 26.54 M | 23.25 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 6.73 M | 1.44 M | 14.03 M | 1.15 M |
| Investing CF | -1.86 M | -1.34 M | -1.8 M | -1.59 M |
| Financing CF | -1.29 M | -0.13 M | -12.13 M | -2.84 M |
| Free CF | 4.87 M | -1.82 M | 11.72 M | -0.44 M |
| Capex | -1.86 M | -3.26 M | -2.31 M | -1.59 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | -8.06% | -16.14% | -0.96% | — |
| Earnings Growth % | -357.07% | -263.25% | 64.11% | — |
| Profit Margin % | -65.51% | -13.18% | -3.04% | -8.4% |
| Operating Margin % | 0.12% | -6.6% | 1.69% | -6.32% |
| Gross Margin % | 57.67% | 58.18% | 58.86% | 53.66% |
| EBITDA Margin % | -53.75% | -1.03% | 7.16% | 0.83% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2026-03-16 | 1:0.1 |